HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer.
Fiche publication
Date publication
juin 2016
Journal
Journal of medical genetics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOUVIER Anne-Marie, Dr CHAPUSOT Caroline, Dr GARRIDO Carmen, Pr LEPAGE Côme
Tous les auteurs :
Buhard O, Lagrange A, Guilloux A, Colas C, Chouchène M, Wanherdrick K, Coulet F, Guillerm E, Dorard C, Marisa L, Bokhari A, Greene M, El-Murr N, Bodo S, Muleris M, Sourouille I, Svrcek M, Cervera P, Blanché H, Lefevre JH, Parc Y, Lepage C, Chapusot C, Bouvier AM, Gaub MP, Selves J, Garrett K, Iacopetta B, Soong R, Hamelin R, Garrido C, Lascols O, André T, Fléjou JF, Collura A, Duval A
Lien Pubmed
Résumé
Every colorectal cancer (CRC) patient should be tested for microsatellite instability (MSI, a marker for defective DNA mismatch repair) as a first screen for Lynch syndrome (LS). In this study, we investigated whether it may be possible to improve the detection of MSI in CRC. We examined whether the HT17 DNA repeat (critical for correct splicing of the chaperone HSP110) might constitute a superior marker for diagnosis of the MSI phenotype in patients with CRC compared with the standard panel of markers (pentaplex).
Référence
J. Med. Genet.. 2016 Jun;53(6):377-84